Potential side effects to GLP-1 agonists: understanding their safety and tolerability

Bibliography

• Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs 2011;21(1):45-57
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol (Oxf) 2012;77(4):489-99
   PubMed Web of Science ®Google Scholar
• Forst T, Pfutzner A. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert Opin Pharmacother 2013;14(16):2281-96
   PubMed Web of Science ®Google Scholar
• Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs 2012;72(12):1679-707
   PubMed Web of Science ®Google Scholar
• Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue; Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155(4):1280-90
   PubMed Web of Science ®Google Scholar
• Richards P, Parker HE, Adriaenssens AE, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 2014;63(4):1224-33
   PubMed Web of Science ®Google Scholar
• Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012;5(2):288-95
   PubMed Web of Science ®Google Scholar
• Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33(12):1491-9
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Goldfine AB. Cardiovascular safety and diabetes drug development. Lancet 2011;377(9770):977-9
   PubMed Web of Science ®Google Scholar
• Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011;2011:215764
   PubMedGoogle Scholar
• Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab 2014;16(8):673-88
   PubMed Web of Science ®Google Scholar
• Bomba M, Ciavardelli D, Silvestri E, et al. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals. Cell Death Dis 2013;4:e612
   PubMed Web of Science ®Google Scholar
• Holscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement 2014;10(1 Suppl):S47-54
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Balas B, Charbonnel B, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 2013;36(3):498-504
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab 2011;96(7):2027-31
   PubMed Web of Science ®Google Scholar
• Labuzek K, Kozlowski M, Szkudlapski D, et al. Incretin-based therapies in the treatment of type 2 diabetes – more than meets the eye? Eur J Intern Med 2013;24(3):207-12
   PubMed Web of Science ®Google Scholar
• Nauck MA. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 2013;36(7):2126-32
   PubMed Web of Science ®Google Scholar
• Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight. Diabetes Obes Metab 2012;14(6):531-8
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87(4):1409-39
   PubMed Web of Science ®Google Scholar
• Ruttimann EB, Arnold M, Hillebrand JJ, et al. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009;150(3):1174-81
   PubMed Web of Science ®Google Scholar
• Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998;275(5 Pt 1):G984-92
   PubMedGoogle Scholar
• Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376(9739):431-9
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-91
   PubMed Web of Science ®Google Scholar
• Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33(6):1300-3
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384(9951):1349-57
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2012;381(9861):117-24
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33(6):1255-61
   PubMed Web of Science ®Google Scholar
• Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28(6):705-14
   PubMed Web of Science ®Google Scholar
• Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375(9733):2234-43
   PubMed Web of Science ®Google Scholar
• Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96(5):1301-10
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35(6):1225-31
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8(12):728-42
   PubMed Web of Science ®Google Scholar
• Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25(12):3049-57
   PubMed Web of Science ®Google Scholar
• Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010;12(4):341-7
   PubMed Web of Science ®Google Scholar
• Sun F, Yu K, Yang Z, et al. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis. Exp Diabetes Res 2013;2012:230624
   Google Scholar
• Jeong KH, Yoo BK. The efficacy and safety of liraglutide. Int J Clin Pharm 2011;33(5):740-9
   PubMed Web of Science ®Google Scholar
• Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013;15(7):642-9
   PubMed Web of Science ®Google Scholar
• Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011(10):CD006423
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375(9724):1447-56
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65(4):397-407
   PubMed Web of Science ®Google Scholar
• Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther 2013;4(1):27-40
   PubMed Web of Science ®Google Scholar
• Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011;11:9
   PubMed Web of Science ®Google Scholar
• Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm 2013;35(2):159-72
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013;36(10):2945-51
   PubMed Web of Science ®Google Scholar
• Davies MJ, Kela R, Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13(3):207-20
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35(2):252-8
   PubMed Web of Science ®Google Scholar
• Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:1
   Web of Science ®Google Scholar
• Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010;9:6
   PubMed Web of Science ®Google Scholar
• Barragan JM, Rodriguez RE, Eng J, Blazquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 1996;67(1):63-8
   PubMed Web of Science ®Google Scholar
• Barragan JM, Eng J, Rodriguez R, Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999;277(5 Pt 1):E784-91
   PubMed Web of Science ®Google Scholar
• Valensi P, Chiheb S, Fysekidis M. Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter. Diabetologia 2013;56(6):1196-200
   PubMed Web of Science ®Google Scholar
• Nathanson D, Ullman B, Lofstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012;55(4):926-35
   PubMed Web of Science ®Google Scholar
• Linnebjerg H, Seger M, Kothare PA, et al. A thorough QT study to evaluate the effects of singledose exenatide 10 mug on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther 2011;49(10):594-604
   PubMed Web of Science ®Google Scholar
• Darpo B, Sager P, MacConell L, et al. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol 2012;75(4):979-89
   Web of Science ®Google Scholar
• Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;49(11):1353-62
   PubMed Web of Science ®Google Scholar
• Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151(4):1473-86
   PubMed Web of Science ®Google Scholar
• Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012;153(3):1538-47
   PubMed Web of Science ®Google Scholar
• FDA. Endocrinologic and Metabolic Drugs Advisory Committee. Liraglutie injection. April 2 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/Committees%20MeetingMaterials/Drugs/End ocrinologicandMetabolicDrugsAdvisory Committee/UCM151129.pdf [Last accessed date 3 February 2014]
   Google Scholar
• European Medical Agency (EMA). Assessment report for Byetta. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000698/WC500128211.pdf [Last accessed 12 February 2014]
   Google Scholar
• Waser B, Beetschen K, Pellegata NS, Reubi JC. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 2011;94(4):291-301
   PubMed Web of Science ®Google Scholar
• Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2011;97(1):121-31
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for Bydureon. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002020/WC500108239.pdf [Last accessed 3 February 2014]
   Google Scholar
• European Medicines Agency. Assesment report for Victoza. 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf [Last accessed 3 February 2014]
   Google Scholar
• Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011;96(3):853-60
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for Lixisenatide. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002445/WC500140449.pdf [Last accessed 11 February 2014]
   Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141(1):150-6
   PubMed Web of Science ®Google Scholar
• Koehler JA, Baggio LL, Lamont BJ, et al. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58(9):2148-61
   PubMed Web of Science ®Google Scholar
• Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61(5):1243-9
   PubMed Web of Science ®Google Scholar
• Malhotra R, Singh L, Eng J, Raufman JP. Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regul Pept 1992;41(2):149-56
   PubMed Web of Science ®Google Scholar
• Fehmann HC, Goke B, Weber V, et al. Interaction of glucagon-like peptide-1 (7-36)amide and cholecystokinin-8 in the endocrine and exocrine rat pancreas. Pancreas 1990;5(3):361-5
   PubMed Web of Science ®Google Scholar
• Zhou J, Montrose-Rafizadeh C, Janczewski AM, et al. Glucagon-like peptide-1 does not mediate amylase release from AR42J cells. J Cell Physiol 1999;181(3):470-8
   PubMed Web of Science ®Google Scholar
• Tatarkiewicz K, Smith PA, Sablan EJ, et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010;299(6):E1076-86
   PubMed Web of Science ®Google Scholar
• Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2009;53(1):153-9
   PubMed Web of Science ®Google Scholar
• Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006;29(2):471
   PubMed Web of Science ®Google Scholar
• FDA safety alert on Byetta. 2007. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm150839.htm [Last accessed 14 February 2014]
   Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173(7):534-9
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25(4):1019-27
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33(11):2349-54
   PubMed Web of Science ®Google Scholar
• Endocrine and Metabolic Drug Advisor Commettee. Liraglutide (Injection) for Treatment of Patients with type 2 Diabetes NDA 22-34 Briefing Document. 2009
   Google Scholar
• Funch D, Gydesen H, Tornoe K, et al. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab 2013;16(3):273-5
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Nardini C, et al. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract 2014;103(2):269-75
   PubMed Web of Science ®Google Scholar
• Giorda CB, Picariello R, Nada E, et al. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Lancet Diabetes Endocrinol 2014;2(2):111-15
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report for GLP-1 based therapies. July 25 2013. Available from: http://www.emaeuropa.eu/docs/en_GB/document_library/Report/2013/08/WC500147026.pdf [Last accessed date 11 February 2014]
   Google Scholar
• Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014;348:g2366
   PubMed Web of Science ®Google Scholar
• Pancreatic cancer associated with Exenatide (Byetta). Arzneimittelkommission der Deutschen ärzteschaft (Drug Commission of the German Medical Association). “Aus der UAWDatenbank“: Pankreaskarzinome im Zusammenhang mit Exenatid (Byetta®). Dtsch Arztebl 2011.108:A-1080
   Google Scholar
• Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467(7319):1114-17
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl 3):57-64
   PubMed Web of Science ®Google Scholar
• Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013;36(Suppl 2):S245-52
   PubMed Web of Science ®Google Scholar
• Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62(7):2595-604
   PubMed Web of Science ®Google Scholar
• Bonner-Weir S, In’t Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab 2014;16(7):661-6
   PubMed Web of Science ®Google Scholar
• Madsbad S. Treatment of type 2 diabetes with incretin-based therapies. Lancet 2009;373(9662):438-9
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 2014;370(9):794-7
   PubMed Web of Science ®Google Scholar
• Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62(7):2178-80
   PubMed Web of Science ®Google Scholar
• Montilla S, Marchesini G, Sammarco A, et al. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ahren B, Leguizamo Dimas A, Miossec P, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36(9):2543-50
   PubMed Web of Science ®Google Scholar
• Pinget M, Goldenberg R, Niemoeller E, et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 2013;15(11):1000-7
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36(9):2489-96
   PubMed Web of Science ®Google Scholar
• Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013;36(9):2497-503
   PubMed Web of Science ®Google Scholar
• Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med 2013;31(2):176-84
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26(3):268-78
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32(1):84-90
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-30
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52(10):2046-55
   PubMed Web of Science ®Google Scholar
• Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 2012;9(1):17-29
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014;57(7):1320-4
   PubMed Web of Science ®Google Scholar